Mirum Pharmaceuticals Inc [MIRM] stock is trading at $73.82, up 1.33%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MIRM shares have gain 2.89% over the last week, with a monthly amount drifted -1.42%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mirum Pharmaceuticals Inc [NASDAQ: MIRM] stock has seen the most recent analyst activity on September 24, 2025, when TD Cowen initiated its Buy rating and assigned the stock a price target of $95. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $48 on April 17, 2024. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $58 on December 18, 2023. In a note dated November 13, 2023, Morgan Stanley initiated an Overweight rating and provided a target price of $60 on this stock.
Mirum Pharmaceuticals Inc [MIRM] stock has fluctuated between $36.88 and $78.10 over the past year. Currently, Wall Street analysts expect the stock to reach $85 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $73.82 at the most recent close of the market. An investor can expect a potential return of 15.14% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
Mirum Pharmaceuticals Inc [NASDAQ:MIRM] reported sales of 429.16M for the trailing twelve months, which represents a growth of 64.09%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -0.13%, Pretax Profit Margin comes in at -0.13%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.08, Equity is -0.25 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 71.68 points at the first support level, and at 69.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 77.25, and for the 2nd resistance point, it is at 80.69.
Ratios To Look Out For
For context, Mirum Pharmaceuticals Inc’s Current Ratio is 3.13. Further, the Quick Ratio stands at 2.97, while the Cash Ratio is 1.58. Considering the valuation of this stock, the price to sales ratio is 8.64, the price to book ratio is 14.48.
Transactions by insiders
Recent insider trading involved Brege Laura, Director, that happened on Sep 11 ’25 when 17000.0 shares were sold. CHIEF FINANCIAL OFFICER, BJERKHOLT ERIC completed a deal on Sep 12 ’25 to sell 9578.0 shares. Meanwhile, Director LAURA BREGE bought 17000.0 shares on Sep 11 ’25.
